Previous close | 62.20 |
Open | 62.40 |
Bid | 64.40 |
Ask | 74.00 |
Strike | 310.00 |
Expiry date | 2024-06-21 |
Day's range | 62.20 - 62.60 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?